Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced non-
small cell lung carcinoma (NSCLC). Building off of this, it has been hypothesized that the …
small cell lung carcinoma (NSCLC). Building off of this, it has been hypothesized that the …
Spatial dynamics of CD39+CD8+ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer
K Tanoue, H Ohmura, K Uehara, M Ito… - Nature …, 2024 - nature.com
Despite the success of immune checkpoint blockade (ICB) therapy for esophageal
squamous cell cancer, the key immune cell populations that affect ICB efficacy remain …
squamous cell cancer, the key immune cell populations that affect ICB efficacy remain …
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Adding anti–programmed cell death protein 1 (anti–PD-1) to 5-fluorouracil (5-FU)/platinum
improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To …
improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To …
Integrating on-treatment modified Glasgow prognostic score and imaging to predict response and outcomes in metastatic renal cell carcinoma
Importance In the era of immuno-oncology, imaging alone seems to be insufficient to capture
treatment responses, as patients with stable disease treated with immunotherapy have a …
treatment responses, as patients with stable disease treated with immunotherapy have a …
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data
SK Yoo, CW Fitzgerald, BA Cho, BG Fitzgerald… - Nature Medicine, 2025 - nature.com
Predicting whether a patient with cancer will benefit from immune checkpoint inhibitors (ICIs)
without resorting to advanced genomic or immunologic assays is an important clinical need …
without resorting to advanced genomic or immunologic assays is an important clinical need …
[HTML][HTML] Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung …
Introduction A large number of patients with non-small cell lung cancer (NSCLC) on immune
checkpoint inhibition (ICI) achieve stable disease (SD) as the best overall response, which is …
checkpoint inhibition (ICI) achieve stable disease (SD) as the best overall response, which is …
On-treatment modified Glasgow prognostic score provides predictive information complementary to radiological staging in metastatic urothelial carcinoma on …
In the immunotherapy era it is difficult to predict patient prognosis on the basis of radiological
staging alone, especially for the subgroup with stable disease (SD), which encompasses a …
staging alone, especially for the subgroup with stable disease (SD), which encompasses a …
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
Purpose To evaluate a new class of blood-based biomarkers, anti-frameshift peptide
antibodies, for predicting both tumor responses and adverse immune events to immune …
antibodies, for predicting both tumor responses and adverse immune events to immune …
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials
T Kus, I Cicin - Immunotherapy, 2024 - Taylor & Francis
A consensus guideline, iRECIST, was developed by the Response Evaluation Criteria in
Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in …
Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in …
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD)
have an unmet clinical need to help guide early treatment adjustments. OBJECTIVE: To …
have an unmet clinical need to help guide early treatment adjustments. OBJECTIVE: To …